Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Follow-On Growth Hormone Has Precedent, Sandoz Says In Response To Pfizer

Executive Summary

FDA's approval of Novo Nordisk's GlucaGen demonstrates that the agency has the legal authority to approve a follow-on version of human growth hormone, Sandoz maintains

You may also be interested in...



Follow-On And Wait: FDA Defers Action On Sandoz’s Human Growth Hormone

Sandoz is presenting FDA's deferral of its decision on approval of the company's recombinant human growth hormone Omnitrope as essentially a tentative approval

Follow-On And Wait: FDA Defers Action On Sandoz’s Human Growth Hormone

Sandoz is presenting FDA's deferral of its decision on approval of the company's recombinant human growth hormone Omnitrope as essentially a tentative approval

FDA Follow-On Biologics Public Meeting Slated For Early ’05

FDA and the Drug Information Association are looking at dates in early 2005 for a public meeting on scientific issues surrounding the development of follow-on biologics

Related Content

Topics

UsernamePublicRestriction

Register

PS044350

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel